Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy Volunteers

Keyphrases

• Healthy Volunteers 100%
• Multiple Ascending Dose 100%
• First-in-human 100%
• Adverse Events 75%
• Cerebrospinal Fluid 50%
• Central Nervous System 50%
• Pharmacokinetics 50%
• Tolerability 50%
• Safety Assessment 50%
• Vital Signs 50%
• Microglia 25%
• Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) 25%
• Placebo 25%
• CSF1R 25%
• Monoclonal Antibody 25%
• Dose Effect 25%
• Serious Adverse Events 25%
• Safety Activity 25%
• Target Engagement 25%
• Clinical Laboratory 25%
• Multiple Dose 25%
• Clinically Significant Change 25%
• Pruritus 25%
• Pharmacodynamics 25%
• Clinical Development 25%
• Osteopontin 25%
• Cerebrospinal Fluid Samples 25%
• Pharmacodynamic Biomarker 25%
• Pharmacokinetic Effects 25%
• Pharmacological Activities 25%
• Laboratory Evaluation 25%
• Biomarker Analysis 25%
• Repeated Dose 25%
• Pharmacokinetic Evaluation 25%
• STREM2 25%
• Secreted Phosphoprotein 1 (SPP1) 25%
• Non-compartmental Analysis 25%
• Laboratory Assessment 25%
• Dose Administration 25%
• Monthly Dosing 25%
• Adult-onset Leukoencephalopathy with Axonal Spheroids and pigmented Glia 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Normal Human 100%
• Pharmacokinetics 100%
• Pharmacodynamics 50%
• Tolerability 50%
• Osteopontin 50%
• Safety Assessment 50%
• Triggering Receptor Expressed on Myeloid Cells 2 50%
• Placebo 25%
• Receptor 25%
• Biological Marker 25%
• Colony Stimulating Factor 1 25%
• Pruritus 25%
• Pharmacological Activity 25%
• Human Monoclonal Antibody 25%
• Leukoencephalopathy 25%